Drug intelligence / Profile preview

FabenCOV

Development stage: Unknown
Lead developer: Fabentech
Modality: Antibody-Based Therapeutics
Administration: Intravenous

Overview

FabenCOV is an equine-derived polyclonal antibody therapy consisting of purified F(ab')2 fragments, developed by Fabentech for the treatment of COVID-19. By utilizing a polyclonal approach, the drug targets multiple epitopes on the SARS-CoV-2 spike protein, which is intended to provide broader protection against viral variants compared to monoclonal antibodies. The mechanism involves direct neutralization of the virus, preventing its attachment and entry into human cells. FabenCOV is being advanced through the EPIC-CROWN-2 consortium and has entered Phase 2 clinical testing to evaluate its safety and efficacy in patients with SARS-CoV-2 infection.

Other names: Fabentech SARS-CoV-2 polyclonal antibody

Targets

SARS-CoV-2 spike

Beyond the preview

Go deeper on FabenCOV.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FabenCOV.

Explore the full profile